Fund Size Statistics - The top three equity ETF types by fund size change are: Scale Index ETF (¥15.406 billion), Cross-border Industry Index ETF (¥6.624 billion), and Strategy Index ETF (¥5.384 billion) [9] - The bottom three equity ETF types by fund size change are: Theme Index ETF (-¥26.004 billion), Cross-border Scale Index ETF (-¥1.807 billion), and Cross-border Theme Index ETF (¥0.203 billion) [9] - The top three equity ETF products by fund size change are: CSI 500 ETF (¥2.832 billion), Chemical ETF (¥2.386 billion), and HuShen 300 ETF (¥2.229 billion) [9] - The bottom three equity ETF products by fund size change are: Communication ETF (-¥30.885 billion), Non-ferrous Metals ETF (-¥3.932 billion), and Gold Stock ETF (-¥2.963 billion) [13] Market Outlook - The macro timing model for February 2026 has a score of 0, indicating a historical 78.57% probability of the full A index rising in the following month, with an average increase of 3.37% [23] - A-shares are expected to experience a short-term volatile market, influenced by liquidity from overseas markets and the recent AI bubble discussions affecting tech growth stocks [23] - The recommendation is to adopt a balanced ETF allocation strategy due to the anticipated short-term fluctuations in the market [60]

开盘后直线跳水，一条直线直接打到-2.2%，随后触底反弹，截至收盘恒生指数下跌1.21%。互联网跌幅 居前，大消费、科技等紧随其后，恒生医疗逆势红盘。 恒生互联网大幅低开后冲高回落，盘中一度大跌2.17%，截至收盘下跌1.19%。阿里巴巴下跌2.88%美团 下跌2.56%，快手下跌2.4%，地平线机器人、网易、百度等股跌幅均在2%上方。 大消费低开高走但整体弱势，截至收盘下跌0.93%。名创优品下跌4.42%，京东健康、老铺黄金、百济 神州、康师傅控股等跌幅均在2%上方；零跑汽车逆势上涨5.84%，理想汽车、蒙牛乳业等股涨幅均在 3%上方。 恒生医疗低开高走，逆势收涨，截至收盘上涨0.45%。其中药明康德上涨1.68%，中国生物上涨0.78%， 药明生物上涨0.43%。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ ...

Group 1 - The Forbes China Year-End Gala held on February 4, 2026, in Shanghai gathered outstanding entrepreneurs and industry leaders from technology, healthcare, semiconductors, and investment sectors to discuss future trends in artificial intelligence, hard technology, biomedicine, and business civilization [2] - Forbes China has been releasing various rankings since entering the Chinese market in 2003, including the Best CEO in China and the Top 50 Innovative Companies in China, which serve as important references for observing changes in China's business society [2] - The event featured a forum with keynote speeches and roundtable discussions covering topics such as healthcare, technology, talent, and sustainable development, aimed at exploring industry development trajectories and prospects [4] Group 2 - The keynote speech by Han Xu, CEO of WeRide, emphasized the strategic significance of autonomous driving as the first large-scale application of physical AI, predicting that within five years, everyone could stop driving, leading to the era of household service robots [6] - Chen Zhisheng, CEO of WuXi Biologics, forecasted that tumors could become controllable chronic diseases within five years, similar to diabetes, and discussed the transformative application of digital technology in drug production [12] - Xu Siqing, founder of Alpha Community, highlighted the dual nature of technological advancement, particularly in AI, which presents both opportunities and challenges to existing human life orders [16] Group 3 - Zhang Hua, founder and chairman of Shibang Group, warned that the era where labor is no longer a necessity is approaching, urging companies to design new job structures for collaboration between humans and intelligent agents [18] - Zhu Jia, partner at Guanghe Venture Capital, pointed out that the core bottleneck limiting AI development is not semiconductor chips but power supply, which is driving nuclear fusion technology towards commercialization [20] - The roundtable discussions included insights on the semiconductor industry's supply-demand mismatch, with Wu Shengwu, chairman of Rongxin Semiconductor, noting a structural contradiction where high-end demand faces capacity shortages while non-specialty processes are oversupplied [27] Group 4 - Liu Yuqing, assistant president of Huafeng Technology Group, emphasized the critical role of advanced packaging in enhancing computing power in the post-Moore's Law era, advocating for a focus on deepening capabilities in the domestic equipment sector [29] - Fang Ling, co-founder of CGL, observed a shift in talent competition within the semiconductor industry from purely technical talent to composite talent with commercial awareness, predicting that AI will exacerbate workplace differentiation [31] - The event also recognized companies like Huafeng Technology and Microchip Technology for their innovative contributions to the industry, awarding them the "2025 Forbes China Innovation Power 50" [58]

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Investment Rating - The report indicates a positive outlook for the pharmaceutical industry, with a recommendation for investment based on favorable fundamentals [17]. Core Insights - The Hong Kong pharmaceutical sector outperformed the Hang Seng Index in January, with the Hang Seng Healthcare Index rising by 8.6%, exceeding the index by 1.7 percentage points. This was driven by several factors, including profit warnings from CXO sector companies, advancements in internet healthcare, and supportive policies from the National Healthcare Security Administration (NHSA) for high-quality surgical robots [1][7]. - The NHSA has issued guidelines to support the pricing of high-quality surgical robots, allowing for premium pricing based on their advanced capabilities and precision in complex surgeries [3][15]. - The State Drug Administration continues to back the development of high-quality innovative drugs, emphasizing clinical value and providing market exclusivity for certain medications, including those for rare diseases and pediatric use [2][14]. Summary by Sections Industry Performance - The pharmaceutical industry in Hong Kong showed strong performance in January, with significant contributions from the CXO sector and internet healthcare companies like JD Health and Ark Health, which reported positive earnings forecasts [1][7]. Policy Support - Recent revisions to the Drug Administration Law emphasize support for innovative drug development, including streamlined approval processes and enhanced regulatory oversight to ensure drug safety and quality [2][14]. - The NHSA's new pricing guidelines for surgical robots aim to incentivize the use of advanced medical technologies, potentially leading to increased revenue for companies involved in this sector [3][15]. Company Recommendations - China Biologic Products (1177 HK) is expected to see double-digit sales growth by 2025, bolstered by its acquisition of Haogiya Biotech, which specializes in small nucleic acid drugs [4][16]. - WuXi AppTec (2359 HK) and WuXi Biologics (2269 HK) have also shown promising earnings forecasts, indicating a recovery in demand within the CXO sector [4][16]. - The report highlights the potential of leading medical AI platform companies, such as Insilico Medicine (3696 HK), which has secured multiple overseas licensing deals, reflecting high industry recognition for its capabilities in enhancing pharmaceutical R&D efficiency [4][16].

Core Viewpoint - The article discusses the poor performance of actively managed equity funds established in 2021, with over 50% of them still showing negative returns despite the A-share market recovering above 4000 points [1]. Fund Performance Summary - A total of 667 actively managed equity funds established in 2021 were analyzed, revealing that approximately 362 funds have negative returns since inception, accounting for over 50% of the sample [1]. - Among these, 86 funds have experienced declines of over 30%, and 34 funds have seen declines exceeding 40% [1]. - Specific funds such as Qianhai Kaiyuan Public Health Theme Select and others have reported losses greater than 50% since their inception [1]. Specific Fund Data - Qianhai Kaiyuan Public Health Stock A/C, established on March 25, 2021, has a return of -57.80% and -58.60% as of February 5, 2026, with a cumulative loss nearing 60% [2]. - The fund's top ten holdings include companies like Tigermed, WuXi AppTec, and BeiGene [1]. - Qianhai Kaiyuan Public Health Stock A/C has a scale of 0.83 billion yuan as of December 31, 2025 [2]. Additional Fund Performance - Qianhai Kaiyuan Quality Enterprises 6-Month Holding Mixed A/C, established on January 8, 2021, has cumulative returns of -40.78% and -43.14% [3]. - The fund's top holdings include major companies such as Tencent and Alibaba, but its performance has been subpar since 2026 [4].

当前港股科技板块极高的性价比，或是南向资金持续抢筹的重要因素。 港股新消费、新能源汽车、创新药等板块连续数月下跌后，已率先展开反弹，预计在南向资金持续加持 下，港股互联网软件应用板块的修复也即将展开。 2月6日，南向资金继续加码涌入港股市场，半日净流入105亿港元。2026年开年以来，南向资金已累计 净流入超1200亿港元，2月4日、2月5日分别净流入133亿港元、249亿港元。 关注港股通科技ETF基金（159101.SZ）及其联接C（025806.OF），被动跟踪国证港股通科技指数，除 了覆盖AI互联网传媒板块，还囊括了新能源汽车（比亚迪（002594）股份/理想汽车/小鹏汽车）和创新 药（药明生物/百济神州）等，成分股全部为港股通标的，不受QD外汇额度限制，流动性更优。港股通 科技ETF基金（159101.SZ）在深圳证券交易所上市，并支持T+0日内灵活回转交易，为A股投资者提供 低门槛投资渠道，免去开港股通和换汇的麻烦。 "南向资金"是指内地资金从上交所、深交所，借道港股通渠道，向南流入香港证券交易所。自2014年开 通沪港通、深港通以来，南向资金动向往往被视为港股市场重要的"风向标"。例如，2024 ...

Group 1 - The Hang Seng Index and Hang Seng Tech Index closed higher on February 5, with the CSI Hong Kong Stock Connect Technology Index rising by 0.58% [1] - Notable performers among the index constituents included Horizon Robotics-W, which rose over 3%, and Kingdee International and Xiaomi Group-W, which both increased by nearly 3% [1] - The Hong Kong Tech ETF Tianhong (159128) saw a trading volume exceeding 160 million yuan, with a net subscription of over 80 million units on the same day, marking 18 consecutive trading days of net inflow totaling over 550 million yuan [1] Group 2 - The Hong Kong Tech ETF Tianhong (520920) closely tracks the Hang Seng Tech Index, focusing on leading technology companies in Hong Kong, and can invest in quality tech companies not included in the Hong Kong Stock Connect through the QDII mechanism [2] - Meituan announced on February 5 its plan to acquire all issued shares of fresh e-commerce company Dingdong for 717 million USD, which will make Dingdong an indirect wholly-owned subsidiary of Meituan, with its financial results incorporated into Meituan's financial statements [2] - Guosen Securities noted that the rebound of the US dollar index and rising US Treasury yields have negatively impacted the capital flow in Hong Kong stocks, but the appreciation of the RMB and stable earnings revisions in Hong Kong stocks maintain a positive outlook for the market [2]

Core Viewpoint - The Hong Kong biotechnology sector is experiencing a significant upward trend, with notable gains in various stocks, indicating positive market sentiment in the industry [1] Group 1: Stock Performance - Nocare Biopharma (09969.HK) has seen an increase of over 4% [1] - Other companies such as Zai Lab (09688.HK), WuXi AppTec (02359.HK), WuXi Biologics (02269.HK), and Innovent Biologics (02696.HK) are also witnessing upward movement in their stock prices [1]

（文章来源：每日经济新闻） 每经AI快讯，2月5日，港股生物医药板块震荡走高，诺诚健华(09969.HK)涨超4%，再鼎医药 (09688.HK)、药明康德(02359.HK)、药明生物(02269.HK)、复宏汉霖(02696.HK)等个股跟涨。 ...